Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...
An experimental drug GSK licensed from Hansoh Pharma has succeeded in a late-stage study in China, boosting the outlook for a therapy the British pharmaceutical company has already advanced into a ...
U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...
Today, a brief rundown of news involving Prime Medicine and Saol Therapeutics, as well as updates from Revolution Medicines and Cyllene Therapeutics that you may have missed.
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...
The Food and Drug Administration has cleared a new treatment from Vera Therapeutics in the latest step forward for an emerging class of medications that have shown the ability to combat a rare and ...
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results